DOBESIL

Indications

• Diabetic retinopathy
• Chronic venous insufficiency
• Microangiopathies

Dosage

Children: Paediatric dosing information is not provided, refer to the BNF for Children for appropriate guidance.

Adults: The typical adult dosage is 500 mg taken orally, three times daily. The duration of treatment and specific indications should be guided by clinical judgment and individual patient response.

Mechanism of action

Dobesilate is believed to exert its effects by stabilizing capillary membranes and reducing their permeability to plasma proteins. It also inhibits the release of inflammatory mediators from activated endothelial cells, leading to a reduction in edema and inflammation. This action contributes to its therapeutic effects in microangiopathies and vascular disorders.

Pharmacodynamics

Dobesilate exhibits vasoprotective properties, which involve actions on the vascular endothelium, providing protection against damage and reducing leakage of plasma proteins. Its anti-inflammatory effects may also contribute to reducing the progression of diseases associated with microcirculation disturbances. The drug has also shown to have positive effects on blood flow in microcirculation by improving the rheological properties of blood.

Pharmacokinetics

Dobesilate is absorbed after oral administration, though the specifics of its bioavailability are not well established. It undergoes hepatic metabolism, and its elimination half-life is approximately 3-4 hours. The drug is primarily excreted via the kidneys, and dose adjustments may be necessary in patients with renal impairment to avoid accumulation.

Contra-indications

• Hypersensitivity to dobesilate or any of its components
• Severe renal impairment

Adverse effects

• Gastrointestinal disturbances
• Skin rashes
• Headache
• Dizziness
• Fatigue
• Nausea

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of hypersensitivity

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Dobesilate should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether dobesilate is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store below 25 degrees Celsius, in a dry place, protected from light.

Formulations

• Capsules
• Tablets
• Oral suspension